Skip to content
20-F

Annual Report (Foreign)

Chemomab Therapeutics Ltd. CMMB

0001178913-25-001205

← back to feed
Filed
Apr 4, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Dec 31, 2024 377.13M sh
Operating Income FY 2024 · Dec 31, 2024 −$103M
Cash And Equivalents FY 2024 · Dec 31, 2023 $9.29M
Current Liabilities FY 2024 · Dec 31, 2023 $4.84M
Total Liabilities FY 2024 · Dec 31, 2023 $5.15M
Current Assets FY 2024 · Dec 31, 2023 $20.9M
Total Assets FY 2024 · Dec 31, 2023 $22.15M
Shares Diluted FY 2024 · Dec 31, 2022 227.59M sh
Capex FY 2024 · Dec 31, 2022 $68K
Operating Cash Flow FY 2024 · Dec 31, 2022 −$20.37M
Eps Diluted FY 2024 · Dec 31, 2022 $0.12
Eps Basic FY 2024 · Dec 31, 2022 $0.12
Sga Expense FY 2024 · Dec 31, 2022 $11.56M
Rd Expense FY 2024 · Dec 31, 2022 $16.98M
Net Income FY 2024 · Dec 31, 2022 −$27.65M
Cost Of Revenue FY 2024 · Dec 31, 2022 $5.14M
Stockholders Equity FY 2024 · Dec 31, 2021 $61.47M